Loading
Loading
Research Overview
Binds androgen receptors to upregulate nitrogen retention, muscle protein synthesis, and satellite cell activation. Non-aromatising DHT derivative — does not convert to oestrogen. Reduces SHBG, increasing free androgen fraction. Directly stimulates osteoblast activity contributing to bone density effects.
Oxandrolone (trade name Anavar) is a dihydrotestosterone-derived anabolic-androgenic steroid first synthesised in the 1960s. Unlike many anabolic steroids, it cannot be converted to oestrogen via aromatisation, and its androgenic potency relative to its anabolic activity is considered low compared to testosterone. These properties have made it a frequently studied compound in both clinical and research contexts.
Decades of published research have examined oxandrolone in populations including burn patients, HIV-associated wasting, Turner syndrome, and paediatric short stature. Preclinical and clinical studies consistently document lean mass preservation and modest increases in nitrogen retention. Hepatic stress, lipid alterations, and axis suppression remain the most frequently characterised adverse findings.
In the research and performance community, oxandrolone is one of the most widely studied oral anabolic agents. Its oral bioavailability, relatively short half-life (~9–10 hours), and moderate suppression profile are frequently cited in comparative AAS pharmacology literature.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Listed as prohibited under WADA anti-doping regulations
Prescription availability in Australia and internationally
In Australia, anavar (oxandrolone) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Anavar (Oxandrolone) research is most relevant to protocols examining:
Muscle wasting and catabolic state research
Bone density investigation in androgen-deficient models
Burn and wound healing recovery studies
Comparative AAS pharmacology reference compound
Initial phase
Effects begin quickly. Initial signalling starts within the first few days. Start at the lowest dose and assess tolerance.
Early response
Measurable effects begin to establish. Mid-cycle assessment is appropriate at this point in well-designed protocols.
Peak activity window
Primary outcomes are typically strongest in this window. Human trial literature provides benchmarks for comparison.
Washout & review
Allow full washout (~5× half-life: ~9–10 hours). Review data, confirm baseline recovery before any repeat protocol.
Binds androgen receptors to upregulate nitrogen retention, muscle protein synthesis, and satellite cell activation. Non-aromatising DHT derivative — does not convert to oestrogen. Reduces SHBG, increasing free androgen fraction. Directly stimulates osteoblast activity contributing to bone density effects.
| Parameter | Value |
|---|---|
| Dose range | Research doses: 10–80 mg/day oral (clinical literature range) |
| Schedule | Daily, split dosing common in research protocols |
| Route | Oral |
| Half-life | ~9–10 hours |
17-alpha-alkylated
Alcohol: hepatotoxic synergy
Anavar is 17-alpha-alkylated; concurrent alcohol use significantly elevates liver enzyme (ALT/AST) burden
Warfarin / anticoagulants: Anavar potentiates anticoagulant effect
INR monitoring essential; bleeding risk elevated
Insulin / oral hypoglycaemics
Anavar reduces insulin sensitivity in some models; glucose monitoring required
Corticosteroids (prednisone)
opposing catabolic/anabolic effects; cortisol blunts the anabolic response
Cocaine / amphetamines / meth
dangerous cardiovascular strain alongside an anabolic agent suppressing HDL cholesterol
MDMA: severe hepatotoxic synergy
both compounds stress liver phase I/II pathways simultaneously
Other 17-AA oral steroids (Dianabol, Winstrol)
stacking multiple alkylated compounds dramatically multiplies liver toxicity risk
SSRIs (fluoxetine, sertraline)
anabolic steroids are associated with mood elevation/aggression; serotonergic modulation may interact unpredictably
Opioids: chronic opioid use suppresses HPG axis further
compounds the testosterone suppression from Anavar
Competitive sports anti-doping: WADA-prohibited
any detected combination triggers sanctions
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.